SELLAS Life Sciences Group, Inc. $SLS Stock Holdings Lifted by Dagco Inc.

Key Points

• Dagco Inc. increased its SELLAS Life Sciences stake by 8.4% in the third quarter, owning 1.34 million shares worth approximately $16.5 million. Institutional investors collectively own 17.38% of SLS.
• SELLAS shares rose 9.8% to $11.51, with a market capitalization of $2.33 billion; the stock has traded between $1.39 and $15.88 over the past year.
• Analyst sentiment is mixed: two analysts rate SLS a Buy and one rates it Sell, resulting in a consensus Hold rating and a $10.00 price target. The company also recently reported a quarterly EPS loss of $0.05, missing estimates by $0.01.

Dagco Inc. increased its holdings in shares of SELLAS Life Sciences Group, Inc. (NASDAQ:SLS - Free Report) by 8.4% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,336,449 shares of the company's stock after purchasing an additional 104,016 shares during the quarter. SELLAS Life Sciences Group makes up 2.9% of Dagco Inc.'s portfolio, making the stock its 11th biggest holding. Dagco Inc. owned approximately 0.66% of SELLAS Life Sciences Group worth $16,452,000 as of its most recent SEC filing.

A number of other institutional investors have also added to or reduced their stakes in the stock. Nykredit A S purchased a new position in shares of SELLAS Life Sciences Group during the second quarter valued at about $27,000. GAMMA Investing LLC grew its holdings in SELLAS Life Sciences Group by 293.2% during the 3rd quarter. GAMMA Investing LLC now owns 2,186 shares of the company's stock valued at $27,000 after purchasing an additional 1,630 shares during the last quarter. California State Teachers Retirement System boosted its holdings in SELLAS Life Sciences Group by 22.4% during the 1st quarter. California State Teachers Retirement System now owns 9,337 shares of the company's stock valued at $39,000 after acquiring an additional 1,709 shares during the period. Wealthfront Advisers LLC bought a new position in shares of SELLAS Life Sciences Group in the first quarter worth about $48,000. Finally, Principal Financial Group Inc. purchased a new position in shares of SELLAS Life Sciences Group during the first quarter worth approximately $53,000. 17.38% of the stock is owned by hedge funds and other institutional investors.

SELLAS Life Sciences Group Stock Up 9.8%

Shares of SLS traded up $1.02 during midday trading on Tuesday, reaching $11.51. The company had a trading volume of 4,660,101 shares, compared to its average volume of 7,871,499. The stock has a market cap of $2.33 billion, a PE ratio of -54.84 and a beta of 2.56. The firm has a 50 day simple moving average of $12.45 and a 200-day simple moving average of $9.98. SELLAS Life Sciences Group, Inc. has a 1-year low of $1.39 and a 1-year high of $15.88.

SELLAS Life Sciences Group (NASDAQ:SLS - Get Free Report) last announced its quarterly earnings results on Tuesday, August 11th. The company reported ($0.05) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.04) by ($0.01).

Analyst Ratings Changes

A number of equities analysts recently commented on SLS shares. Alliance Global Partners reissued a "buy" rating on shares of SELLAS Life Sciences Group in a research note on Wednesday, August 12th. Weiss Ratings reiterated a "sell (d-)" rating on shares of SELLAS Life Sciences Group in a research report on Thursday. Two analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company has an average rating of "Hold" and a consensus target price of $10.00.

SELLAS Life Sciences Group Company Profile

SELLAS Life Sciences Group, Inc is a clinical-stage biopharmaceutical company focused on developing novel cancer therapies. The company's research and development programs are centered on treatments designed to stimulate or restore the immune system's ability to recognize and attack cancer cells, as well as targeted therapies for hematologic malignancies.

SELLAS' lead product candidate is galinpepimut-S (GPS), a multi-peptide immunotherapeutic targeting Wilms' tumor 1 (WT1), a protein expressed in multiple types of cancer.

Want to see what other hedge funds are holding SLS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for SELLAS Life Sciences Group, Inc. (NASDAQ:SLS - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.